Moderna, Inc. (MRNA)
Moderna is a biotechnology company that uses messenger RNA technology to create vaccines and treatments for a wide range of diseases.
Is Moderna, Inc. a good stock for a UK beginner?
The honest version: Moderna is a biotechnology company that uses messenger RNA technology to create vaccines and treatments for a wide range of diseases.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
The mRNA platform becomes a standard for multiple major diseases
Failure to prove the effectiveness of the mRNA platform beyond initial vaccines
What does Moderna, Inc. do?
Moderna became a household name for its COVID-19 vaccine, but it is now working to turn that same technology into a pipeline of treatments for things like cancer and rare genetic conditions. The business earns its keep by researching, developing, and selling these medical products to healthcare providers and governments. Everything turns on whether they can launch new products beyond their initial success and convert today's losses into consistent profits.
On our factor screen it looks strongest on growth and momentum, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 260% over the year
- ✓Low debt - a sturdier balance sheet
- Growth screens high (98/100)
- Pioneering technology platform with broad potential
- Strong cash position from previous vaccine sales
- Large pipeline of potential new medicines
- Quality screens low (23/100)
- Income screens low (16/100)
- Clinical trials failing to meet safety or effectiveness standards
- Regulatory bodies rejecting new drug applications
- Intense competition from established pharmaceutical giants
What do Moderna, Inc.'s numbers mean?
How much money does Moderna, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Moderna, Inc. pay a dividend?
No - Moderna, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Moderna, Inc. report earnings, and how did recent quarters go?
Moderna, Inc. is next scheduled to report on about 2026-11-05 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-31 | $-2.06 | $-1.97 | Beat +4% |
| 2026-04-30 | $-3.88 | $-3.40 | Beat +12% |
| 2026-02-13 | $-2.64 | $-2.11 | Beat +20% |
| 2025-11-06 | $-2.16 | $-0.51 | Beat +76% |
| 2025-08-01 | $-3.00 | $-2.13 | Beat +29% |
| 2025-05-01 | $-3.11 | $-2.52 | Beat +19% |
Across the last 6 quarters here, Moderna, Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Agilent Technologies, Inc.What are the scenarios for Moderna, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Moderna, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Pioneering technology platform with broad potential
- Strong cash position from previous vaccine sales
- Large pipeline of potential new medicines
- Currently operating at a significant financial loss
- High reliance on the success of future, unproven products
- No dividend payments to shareholders
- Clinical trials failing to meet safety or effectiveness standards
- Regulatory bodies rejecting new drug applications
- Intense competition from established pharmaceutical giants
The write-up's own warning lights — if these start happening, the case above changes.
- Consistent quarterly profits being reported
- Multiple successful product launches outside of the COVID-19 space
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.